The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...
Please provide your email address to receive an email when new articles are posted on . The addition of anlotinib to standard of care for newly diagnosed glioblastoma significantly improved PFS in a ...
Hosted on MSN
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Management described seeking an amendment to the VERSATILE-003 protocol to elevate progression-free survival (PFS) as a surrogate primary endpoint, in addition to maintaining median overall survival ...
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback